Deepak Nath Sells 18,007 Shares of Smith & Nephew (LON:SN) Stock

Key Points

• Deepak Nath, an insider at Smith & Nephew plc, sold 18,007 shares at an average price of GBX 1,351, totaling approximately £243,274.57.
• Smith & Nephew's current stock performance shows a market capitalization of £14.78 billion and a P/E ratio of 48.53, reflecting a relatively high valuation.
• Recent analyst ratings indicate a consensus rating of "Hold" for Smith & Nephew, with target prices ranging from GBX 1,300 to GBX 1,438, signaling mixed outlooks from brokerages.

Smith & Nephew plc (LON:SN - Get Free Report) insider Deepak Nath sold 18,007 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of GBX 1,351, for a total value of £243,274.57.

Smith & Nephew Stock Performance

LON SN traded down GBX 2 during trading on Monday, hitting GBX 1,383. The stock had a trading volume of 2,379,900 shares, compared to its average volume of 343,671. The firm has a market cap of £15.16 billion, a P/E ratio of 49.79, a PEG ratio of 0.46 and a beta of 0.62. The company has a 50 day moving average price of GBX 1,180.15 and a 200-day moving average price of GBX 1,103.75. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SN shares. Berenberg Bank upped their price objective on Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the stock a "hold" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. upped their price objective on Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the stock a "hold" rating in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of GBX 1,379.33.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.